Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor [Phase 2]

View source ↗

Summary

Phase 2 trial results assess the efficacy and safety of the ASP0113 CMV vaccine in CMV-seronegative kidney transplant recipients receiving an organ from a CMV-s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• ASP0113

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients | Phase 2 | Status: COMPLETED | Results posted: 2022-01-04